Skip to main content
Click here to get access to our Free Course on Momentum Investing Strategy

NSE · SPARC

SUNPHA ADV

HealthcarePharmaceuticals & Biotechnology₹6169 cr market cap
₹192.57 ▲ +1.29% today As of 19 Nov 2026
52-week low ₹108.7152-week high ₹277.57

-31.5% from the 52-week high · +74.9% above the low

Sun Pharma Advanced Research Co. Ltd. is a bio-pharmaceutical company, which engages in the research and development of pharmaceuticals. The company is headquartered in Mumbai, Maharashtra and currently employs 407 full-time employees. The company went IPO on 2007-07-18. The firm is in the business of research and development (R&D) of pharmaceutical products to unmet medical needs in the areas of oncology, neurodegeneration and immunology. The firm develops New Chemical Entities (NCE), New Biological Entities and reformulated products. Its NCE includes SCC-138, SCO-088, SCO-120 and SCD-044. Its Novel Drug Delivery Systems (NDDS) include Wrap Matrix Technology, Lipexelle technology and TearAct Technology. Wrap Matrix technology is useful to develop controlled release tablets. The company has developed Elepsia XR using Wrap MatrixTM technology. Lipexelle technology for ophthalmic formulations. The company has also developed Xelpros, a BAK free latanoprost eye drop developed using Lipexelle technology. Xelpros is commercialized by its partner in the United States. The company has also developed PDP-716 eye drops for treatment of Glaucoma based on its TearAct technology.

The short version. SUNPHA ADV reported revenue of ₹30 crore for Sep 2026, up 275.0% from a year earlier. Net profit was ₹-24 crore. Return on equity was 116.0% in Mar 2026. Promoter holding was 65.67% in Sep 2026, up 0.00 points over 8 quarters.

1 · The price

How has the stock traded?

SUNPHA ADV trades 31.5% below its 52-week high and 74.9% above its 52-week low.

Change over period: —

1M+2.7%
3M-1.5%
6M+3.5%
1Y+46.1%

2 · The business

Is it growing?

Sales, year on year+275.0%

Sep 2026 revenue of ₹30 cr.

Net margin-81.2%

883.8 pts higher than a year earlier.

Reported results · ₹ crore

Revenue and profit

Show the numbers

Quarterly

Sep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue3040185388102715
Net profit-24-211761-80-76-52-60-80
Net margin %-81.2-52.095.0-951.7-965.0-538.1-221.3-533.3
EPS (₹)-0.75-0.6454.27-2.48-2.34-1.6-1.85-2.45

Annual

FY2026FY2025FY2024
Revenue18797276
Net profit1553-343-387
Net margin %82.7-477.5-512.5
EPS (₹)47.86-10.56-11.93

3 · The quality

How well does it turn capital into profit?

Return on equity was 116.0% in Mar 2026; debt to equity is 0.42.

Profitability · 4 years

Returns and margins

Mar 2026Mar 2025Mar 2024Mar 2023
Return on equity %116.0158.0-307.9—
Return on capital %112.0862.1-154.1—
EBITDA margin %84.5-436.9-354.8—
Net margin %82.2-465.9-368.7—

Compound growth

Revenue vs profit

3 years5 years
Revenue CAGR——
Profit CAGR——
Debt to equity0.42
Interest cover46.5x
Current ratio2.47
P/E ratio3.8

4 · The owners

Who holds it, and are they adding?

Promoter holding65.67%

Unchanged over 8 quarters.

Foreign institutions3.75%

Up 1.52 pts over 8 quarters.

Domestic institutions0.11%

Down 0.53 pts over 8 quarters.

Mutual fund schemes12

+4 versus the previous month.

Shareholding pattern (%)

Quarter by quarter

Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026Change
Promoter65.6765.6765.6765.6765.6765.6765.6765.670.0
FII2.231.451.471.762.042.043.93.75+1.52
DII0.641.130.971.050.780.880.090.11-0.53
Public31.4631.7531.8831.5231.5131.4130.3330.48-0.98

Mutual fund holdings · Oct 2026

12 schemes hold this stock

8 the month before.

  • SAMCO MULTI CAP FUND0.3% of NAV
  • Motilal Oswal Nifty Microcap 250 Index Fund0.2% of NAV
  • Motilal Oswal BSE Healthcare ETF0.1% of NAV
  • Bandhan BSE Healthcare Index Fund0.1% of NAV
  • Motilal Oswal BSE 1000 Index Fund0.01% of NAV
  • Bandhan Nifty Total Market Index Fund0.01% of NAV
  • Angel One Nifty Total Market ETF0.01% of NAV
  • Groww Nifty Total Market Index Fund0.01% of NAV

See what mutual funds are buying

5 · The model view

What does our factor model say?

Factor scores, model flags and screen results for SUNPHA ADV are part of the Wright portfolio review.

Run your free portfolio review

Watchouts

What to review

Model flags are shown inside the portfolio review, alongside your other holdings.

Model ratingLocked
Factor betaLocked
VolatilityLocked

Quick answers

Common questions about SUNPHA ADV

What is the SUNPHA ADV share price?

SUNPHA ADV (SPARC) last closed at ₹192.57, up 1.29% on the day. Its 52-week range is ₹108.71 to ₹277.57.

What is the market cap of SUNPHA ADV?

SUNPHA ADV has a market capitalisation of about ₹6,169 crore. Its price-to-earnings ratio is 3.8.

How are SUNPHA ADV's latest results?

SUNPHA ADV reported revenue of ₹30 crore for Sep 2026, up 275.0% from a year earlier. Net profit was ₹-24 crore. Return on equity was 116.0% in Mar 2026. Promoter holding was 65.67% in Sep 2026, up 0.00 points over 8 quarters.

Who owns SUNPHA ADV?

As of Sep 2026, shareholding was: Promoter 65.67%, FII 3.75%, DII 0.11%, Public 30.48%.

How many mutual funds hold SUNPHA ADV?

12 mutual fund schemes held SUNPHA ADV in October 2026. That compares with 8 the month before.

Corporate actions

Recent dividends, bonuses and splits

  • 16 Mar 2016 · Rights issue 5:116

Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.

Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.